This step ensures that you receive personalized advice and minimize potential risks
Disclosure of interest: All authors: nothing to disclose Poster session I - DIAGNOSIS / ETIOLOGY 04.00 - DIAGNOSIS / ETIOLOGY - 04.01 - DIAGNOSIS/INVESTIGATION OF STROKE ETIOLOGY P327 - ESOC25-999 MICROEMBOLIC SIGNAL DETECTION: A 5-YEAR EXPERIENCE AT A GERMAN NEUROVASKULAR CENTER Lili Laura Bruta 1 , Irena Kovacic 1 , David Pollinger 2 , David Olmes 2 , Ralf Linker 2 , Felix Schlachetzki 1 1 Center for Vascular Neurology and Intensive Care Medicine (Center II) at the Department of Neurology at the University of Regensburg, Regensburg, Germany, 2 Department of Neurology at the University of Regensburg, Regensburg, Germany Background and Aims: Microembolic signal detection (MES-D) is a potent sonographic biomarker for increased stroke risk but still has no widespread impact on stroke therapy
BPC-157 acts on the nitric oxide system and growth factor expression, while TB-500 promotes cell migration via actin upregulation
It is assumed that the dose should cover the entire daily requirement alone
From REDEFINE-1: Nausea: 55% of CagriSema participants vs 12.6% with placebo Constipation: 30.7% vs 11.6% Vomiting: 26.1% vs 4.1% Discontinuation rate: 5.9% vs 3.5% placebo comparable to Wegovy (6.9%) and Zepbound (6.2%) The nausea rate (55%) is higher than the ~4045% typical for semaglutide alone
